Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
News|Articles|September 2, 2003
- Pharmaceutical Technology-09-02-2003
- Volume 27
- Issue 9
Improved Blister Packaging Benefits Consumers, Caregivers, and Drug Makers
Author(s)Hallie Forcinio
New blister packaging offers patient compliance aids, child-resistant mechanisms, and space to include brand information.
Advertisement
Articles in this issue
about 23 years ago
September 2003about 23 years ago
In the Spotlight September 2003about 23 years ago
Counterfeiting, Compliance, and Controlsabout 23 years ago
September 2003about 23 years ago
Disposable Filtration Lightens Cleaning and Validation Loadabout 23 years ago
CROs Hoping for Research Burst in Second Half of 2003Advertisement
Related to this article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Advertisement
Advertisement